Intravitreal triamcinolone

Ophthalmologica

Volumn 225, Issue 1, 2011, Pages 1-20

  Tao, Yong ^a,b   Jonas, Jost B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Diabetic retinopathy; Intraocular steroids; Macular edema; Ocular hypertension, steroid induced; Ocular hypotony; Retinal vein occlusion; Triamcinolone

Indexed keywords

BEVACIZUMAB; FLUOCINOLONE ACETONIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EALES DISEASE; ENDOPHTHALMITIS; EXUDATIVE RETINITIS; FOVEA TELANGIECTASIA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS NEOVASCULARIZATION; IRITIS; LASER COAGULATION; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OPEN ANGLE GLAUCOMA; PHOTODYNAMIC THERAPY; POSTINJECTION INFECTIOUS ENDOPHTHALMITIS; PSEUDOENDOPHTHALMITIS; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA TEAR; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SYMPATHETIC OPHTHALMIA; TELANGIECTASIA; UVEITIS; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE; VOGT KOYANAGI SYNDROME;

EID: 77955190676     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317909     Document Type: Review

References (332)

1. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180.
2. Graham RO, Peyman GA: Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974;92:149-154.
3. Tano Y, Chandler D, Machemer R: Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
4. Tano Y, Sugita G, Abrams G, Machemer R: Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980;89:131-136.
5. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R: The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
6. Schindler RH, Chandler D, Thresher R, Machemer R: The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
7. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-711.
8. Hida T, Chandler D, Arena JE, Machemer R: Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-195.
9. Chandler DB, Hida T, Sheta S, Proia AD, Machemer R: Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol 1987;225:259-265.
10. Coats ML, Peyman GA: Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992;12:46-51.
11. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL: The effects of intravitreal triamcinolone acetonide on experimental preretinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
12. Machemer R: Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina 1996;16:166-167.
13. Machemer R: Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment - proctor lecture. Invest Ophthalmol Vis Sci 1988;29:1771-1783.
14. Jonas JB, Hayler JK, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-1067.
15. Furino C, Micelli Ferrari T, Boscia F, et al: Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 2003;23:771-776.
16. Jonas JB, Sofker A, Hayler J, Degenring RF: Intravitreal crystalline triamcinolone acetonide as an additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy? Acta Ophthalmol Scand 2003;81:663-665. (Pubitemid 37527651)
17. Jonas JB, Sofker A, Degenring R: Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003;13:468-473. (Pubitemid 36807132)
18. Bandello F, Pognuz DR, Pirracchio A, Polito A: Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2004;242:1024-1027.
19. Jonas JB, Sofker A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427. (Pubitemid 32768624)
20. Martidis A, Duker JS, Greenberg PB, et al: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
21. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
22. Audren F, Tod M, Massin P, et al: Pharmacokineticpharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435-3441.
23. Bakri SJ, Beer PM: Intravitreal triamcinolone injection for diabetic macular edema: a clinical and fluorescein angiographic case series. Can J Ophthalmol 2004;39:755-760.
24. Brooks HL Jr, Caballero S Jr, Newell CK, et al: Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-1807.
25. Ciardella AP, Klancnik J, Schiff W, et al: Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004;88:1131-1136.
26. Degenring RF, Kreissig I, Jonas JB: Intraocular triamcinolone for diffuse diabetic macular edema (in German). Ophthalmologe 2004;101:251-254. (Pubitemid 38374452)
27. Jonas JB, Harder B, Kamppeter BA: Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:970-977.
28. Karaçorlu M, Özdemir H, Karaçorlu S, et al: Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye (Lond) 2005;19:382-386.
29. Karaçorlu M, Özdemir H, Karaçorlu S, Alacali N: Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. Int Ophthalmol 2004;25:113-116.
30. Lee WF, Yang CM: Intravitreal triamcinolone injection for macular edema secondary to increased retinal vascular permeability. J Formos Med Assoc 2004;103:692-700.
31. Massin P, Audren F, Haouchine B, et al: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224, discussion 224-225.
32. Micelli Ferrari T, Sborgia L, Furino C, et al: Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 2004;14:321-324.
33. Al-Haddad CE, Jurdi FA, Bashshur ZF: Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am J Ophthalmol 2004;137:1151-1153.
34. Sutter FK, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: threemonth efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
35. Islam MS, Negi A, Vernon SA: Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema. Eye (Lond) 2005;19:1325-1327.
36. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I: Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.
37. Lam DS, Chan CK, Tang EW, et al: Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004;32:569-572.
38. Özkiris A, Evereklioglu C, Öner A, Erkiliç K: Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema. Doc Ophthalmol 2004;109:139-145. (Pubitemid 40468408)
39. Özkiris A, Evereklioglu C, Erkiliç K, Tamçelik N, Mirza E: Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004;14:543-549.
40. Inoue M, Takeda K, Morita K, et al: Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004;138:1046-1048.
41. Jonas JB, Kreissig I, Degenring RF, Kamppeter BA: Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema. Br J Ophthalmol 2005;89:122. (Pubitemid 40040253)
42. Jonas JB, Akkoyun I, Kreissig I, Degenring RF: Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005;89:321-326. (Pubitemid 40327617)
43. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I: Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 2005;123:1338-1343.
44. Gupta R, Negi A, Vernon SA: Severe subconjunctival haemorrhage following intravitreal triamcinolone for refractory diabetic oedema. Eye (Lond) 2005;19:590-591. (Pubitemid 40711718)
45. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K: Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye (Lond) 2005;19:747-751.
46. Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H: Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005;83:132-133.
47. Krepler K, Wagner J, Sacu S, Wedrich A: The effect of intravitreal triamcinolone on diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2005;243:478-481.
48. Lam DS, Chan CK, Mohamed S, et al: Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye (Lond) 2005;19:885-890.
49. Larsson J, Zhu M, Sutter F, Gillies MC: Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
50. Zacks DN, Johnson MW: Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 2005;25:135-140.
51. Flynn HW Jr, Scott IU: Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: it's time for clinical trials. Arch Ophthalmol 2005;123:258-259.
52. Er H, Yilmaz H: Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica 2005;219:394-400.
53. Avitabile T, Longo A, Reibaldi A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
54. Ladjimi A, Zeghidi H, Ben Yahia S, et al: Intravitreal injection of triamcinolone acetonide for the treatment of macular edema (in French). J Fr Ophtalmol 2005;28:749-757. (Pubitemid 41480591)
55. Patelli F, Fasolino G, Radice P, et al: Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005;25:840-845.
56. Khairallah M, Zeghidi H, Ladjimi A, et al: Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates. Retina 2005;25:835-839.
57. Chieh JJ, Roth DB, Liu M, et al: Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005;25:828-834.
58. Tewari HK, Sony P, Chawla R, Garg SP, Venkatesh P: Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders. Eur J Ophthalmol 2005;15:619-626.
59. Gibran SK, Cullinane A, Jungkim S, Cleary PE: Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye (Lond) 2006;20:720-724.
60. Cardillo JA, Melo la Jr, Costa RA, et al: Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563.
61. Özdemir H, Karaçorlu M, Karaçorlu SA: Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema. Am J Ophthalmol 2005;140:251-255.
62. Sørensen TL, Haamann P, Villumsen J, Larsen M: Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand 2005;83:67-70.
63. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB: Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.
64. Nicolo M, Nasciuti F, Lai S, et al: Intravitreal triamcinolone acetonide as primary treatment for diffuse diabetic macular edema: a prospective noncomparative interventional case series. Eur J Ophthalmol 2006;16:129-133.
65. Jonas JB, Kamppeter BA, Harder B, et al: Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207. (Pubitemid 44051133)
66. Jonas JB, Spandau UH, Kamppeter BA, et al: Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006;113:800-804.
67. Desatnik H, Habot-Wilner Z, Alhalel A, et al: The transient efficacy of a single intravitreal triamcinolone acetonide injection for diabetic macular edema. Isr Med Assoc J 2006;8:383-387.
68. Gillies MC, Sutter FK, Simpson JM, et al: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
69. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbauemer U, Harder B: Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema. Eur J Ophthalmol 2006;16:566-572. (Pubitemid 44859665)
70. Ramezani A, Ahmadieh H, Tabatabaei H: Intravitreal triamcinolone reinjection for refractory diabetic macular edema. Korean J Ophthalmol 2006;20:156-161.
71. Selim Kocabora M, Küçüksahin H, Gülkilik G, et al: Treatment of diabetic macular edema with intravitreal triamcinolone acetonide injection: functional and anatomical outcomes (in French). J Fr Ophtalmol 2007;30:32-38.
72. Batioglu F, Özmert E, Parmak N, Çelik S: Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol 2007;27:299-306.
73. Pinheiro A, Serracarbassa PD, Maia OO Jr, Takahashi WY: Macular thickness analysis by optic coherence tomography in refractory diabetic macular edema treated with intravitreous triamcinolone (in Portuguese). Arq Bras Oftalmol 2007;70:784-789.
74. Bardak Y, Çekiç O, Sahin Tig U, Bardak H: Alterations in central retinal sensitivity after intravitreal triamcinolone injection for diffuse diabetic macular edema. Eur J Ophthalmol 2007;17:780-784.
75. Dusová J, Studnicka J, Rencová E, Korda V, Hejcmanová D: Triamcinolone in the treatment of the diabetic macular edema: oneyear results (in Czech). Cesk Slov Oftalmol 2008;64:149-152.
76. Dehghan MH, Ahmadieh H, Ramezani A, Entezari M, Anisian A: A randomized, placebocontrolled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17. (Pubitemid 351308679)
77. Karaçorlu M, Özdemir H, Sentürk F, Arf Karaçorlu S, Uysal O: Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol 2008;18:601-608.
78. Wickremasinghe SS, Rogers SL, Gillies MC, Zhu M, Wong TY: Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:4707-4711.
79. Çekiç O, Bardak Y, Tig US, Yildizoglu U, Bardak H: Quantitative evaluation of reduction of plaque-like hard exudates in diabetic macular edema after intravitreal triamcinolone injection. Int Ophthalmol 2008;28:95-99.
80. Chen SD, Lochhead J, Patel CK, Frith P: Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 2004;88:154-155.
81. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye (Lond) 2005;19:65-71. (Pubitemid 40192642)
82. Tsujikawa A, Fujihara M, Iwawaki T, Yamamoto K, Kurimoto Y: Triamcinolone acetonide with vitrectomy for treatment of macular edema associated with branch retinal vein occlusion. Retina 2005;25:861-867.
83. Çekiç O, Chang S, Tseng JJ, et al: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-855. (Pubitemid 41456575)
84. Karaçorlu M, Özdemir H, Karaçorlu SA: Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 2005;25:856-860.
85. Özkiris A, Evereklioglu C, Erkiliç K, Dogan H: Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye (Lond) 2006;20:13-17.
86. Özkiris A, Evereklioglu C, Erkiliç K, Ilhan O: The efficacy of intravitreal triamcinolone acetonide on macular edema in branch retinal vein occlusion. Eur J Ophthalmol 2005;15:96-101.
87. Krepler K, Ergün E, Saçu S, et al: Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005;83:600-604. (Pubitemid 41488636)
88. Hayashi K, Hayashi H: Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005;139:972-982.
89. Kaiser PK: Steroids for branch retinal vein occlusion. Am J Ophthalmol 2005;139:1095-1096.
90. Lee H, Shah GK: Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005;25:551-555.
91. Salinas-Alamán A, García-Layana A, Sádaba-Echarri LM, Belzunce-Manterola A: Branch retinal vein occlusion treated by intravitreal triamcinolone (in Spanish). Arch Soc Esp Oftalmol 2005;80:463-465.
92. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL: Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2005;36:30-36.
93. Bashshur ZF, Ma'luf RN, Allam S, et al: Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.
94. Bynoe LA, Weiss JN: Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 2003;135:382-384.
95. Çekiç O, Chang S, Tseng JJ, et al: Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25:846-850. (Pubitemid 41456574)
96. Chen SD, Lochhead J, Satchi K, Patel CK, Frith P: Bilateral retinal venous occlusion and unilateral cystoid macular edema in Churg-Strauss syndrome treated with intravitreal triamcinolone. Retina 2005;25:655-657.
97. Chiu YT, Tsai YY, Lin JM: Noninfectious hypopyon after intravitreal triamcinolone acetonide injection for central retinal vein occlusion: a case report. Kaohsiung J Med Sci 2005;21:466-469.
98. Degenring RF, Kamppeter B, Kreissig I, Jonas JB: Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand 2003;81:399-401.
99. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E: Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247-248.
100. Ip M, Kahana A, Altaweel M: Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol 2003;18:67-73.
101. Ip MS, Gottlieb JL, Kahana A, et al: Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136.
102. Ip MS, Kumar KS: Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 2002;120:1217-1219.
103. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 2005;15:751-758. (Pubitemid 43074702)
104. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-783.
105. Karaçorlu M, Özdemir H, Karaçorlu S: Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. Retina 2004;24:324-327.
106. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R: Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004;137:758-760.
107. Krepler K, Ergün E, Saçu S, et al: Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005;83:71-75. (Pubitemid 40326425)
108. Park CH, Jaffe GJ, Fekrat S: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-425.
109. Scott IU, Ip MS: It's time for a clinical trial to investigate intravitreal triamcinolone for macular edema due to retinal vein occlusion: the SCORE study. Arch Ophthalmol 2005;123:581-582.
110. Wakabayashi T, Okada AA, Morimura Y, et al: Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004;24:964-967.
111. Williamson TH, O'Donnell A: Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139:860-866.
112. Bonanomi MT, Susanna R Jr: Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma. Clinics 2005;60:347-350.
113. Intravitreal Triamcinolone Ophthalmologica 2011;225:1-20 15
114. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S: Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001;10:284-287. (Pubitemid 32781343)
115. Jonas JB, Kreissig I, Degenring RF: Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol Scand 2003;81:540-541. (Pubitemid 37265680)
116. Jonas JB, Sofker A: Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization. J Cataract Refract Surg 2002;28:2040-2041.
117. Penfold PL, Gyory JF, Hunyor AB, Billson FA: Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust NZ J Ophthalmol 1995;23:293-298.
118. Challa JK, Gillies MC, Penfold PL, et al: Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust NZ J Ophthalmol 1998;26:277-281.
119. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
120. Jonas JB, Kreissig I, Degenring R: Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:873-874.
121. Penfold PL: Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 2002;86:600-601.
122. Jonas JB, Kreissig I, Hugger P, et al: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003;87:462-468. (Pubitemid 36399037)
123. Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529.
124. Gillies MC, Simpson JM, Luo W, et al: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-673.
125. Spaide RF, Sørenson J, Maranan L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
126. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF: Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-222. (Pubitemid 38176489)
127. Jonas JB, Kreissig I, Degenring RF: Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br J Ophthalmol 2004;88:1557-1562.
128. Rechtman E, Danis RP, Pratt LM, Harris A: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2004;88:344-347.
129. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye (Lond) 2005;19:163-170.
130. Arévalo JF, García RA, Mendoza AJ: Indocyaninegreen- mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005;243:1180-1185.
131. Deckers V, Priem H, Verbraeken H: One year of intravitreal injections of steroids. Bull Soc Belge Ophtalmol 2005:69-77.
132. van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ: Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005;112:1896-1903.
133. Spaide RF, Sørenson J, Maranan L: Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005;25:685-690.
134. Spaide RF, Sørenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304. (Pubitemid 40202568)
135. Larsson J, Gillies MC: Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative agerelated macular degeneration. Clin Experiment Ophthalmol 2005;33:544-545.
136. Nicolo M, Ghiglione D, Lai S, Calabria G: Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005;15:415-419.
137. Jonas JB, Spandau UH, Kamppeter BA, Harder B: Follow-up after intravitreal triamcinolone acetonide for exudative agerelated macular degeneration. Eye (Lond) 2007;21:387-394.
138. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
139. Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
140. Jonas JB, Strueven V, Kamppeter BA, et al: Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration. J Ocul Pharmacol Ther 2006;22:370-376.
141. Ito M, Okubo A, Sonoda Y, Yamakiri K, Sakamoto T: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients. Ophthalmologica 2006;220:118-124.
142. Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ: Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007;27:1205-1213.
143. Lubinski W, Gošawski W, Mozolewska-Piotrowska K, Szych Z, Karczewicz D: Evaluation of visual function among patients with exudative AMD treated with an intravitreal injection of triamcinolone acetonide (in Polish). Ann Acad Med Stetin 2008;54:22-27, discussion 27.
144. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA: Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006;26:602-612.
145. Ruiz-Moreno JM, Montero JA, Zarbin MA: Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 2007;27:458-461.
146. Leparmentier A, Arnaud C, Fournié P, Mathis A, Quintyn JC: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration (in French). J Fr Ophtalmol 2007;30:155-160.
147. Kumar A, Sinha S, Kumar V: Visual acuity and contrast sensitivity outcomes in Indian eyes undergoing photodynamic therapy with intravitreal injection of triamcinolone acetonide in age-related macular degeneration. Indian J Ophthalmol 2007;55:207-211.
148. Chaudhary V, Mao A, Hooper PL, Sheidow TG: Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007;114:2183-2189.
149. Iwama D, Otani A, Sasahara M, et al: Photodynamic therapy combined with lowdose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. Br J Ophthalmol 2008;92:1352-1356.
150. Frimpong-Boateng A, Bunse A, Rüfer F, Roider J: Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol 2009;87:183-187.
151. Weigert G, Michels S, Saçu S, et al: Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360.
152. Gamulescu MA, Schubert K, Thormann S, et al: ITAP: 6-month results of a prospective, randomised phase 3 study for evaluation of the combination therapy of PDT and intravitreal triamcinolone in exudative AMD (in German). Klin Monbl Augenheilkd 2009;226:60-65.
153. Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA: Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005;139:1073-1079.
154. Potter MJ, Szabo SM, Ho T: Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch Clin Exp Ophthalmol 2006;244:639-641.
155. Degenring RF, Jonas JB: Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 2005;83:621.
156. Rechtman E, Allen VD, Danis RP, et al: Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-741.
157. Jonas JB, Hayler JK, Panda-Jonas S: Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch Clin Exp Ophthalmol 2001;239:464-465. (Pubitemid 32694458)
158. Rodriguez ML, Juarez CP, Luna JD: Intravitreal triamcinolone acetonide injection in blind painful eyes: intraocular steroids as a treatment for blind painful red eyes. Eur J Ophthalmol 2003;13:292-297.
159. Heras-Mulero H, García-Layana A, Fernández-Hortelano A, García-Gómez PJ, Sádaba-Echarri LM: Silicone oil hypotonic maculopathy treatment (in Spanish). Arch Soc Esp Oftalmol 2005;80:417-420.
160. Young S, Larkin G, Branley M, Lightman S: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2-6.
161. Benítez del Castillo Sánchez JM, García Sánchez J: Intravitreal injection of triamcinolone acetonide in non-infectious uveitis (in Spanish). Arch Soc Esp Oftalmol 2001;76:661-664.
162. Martidis A, Duker JS, Puliafito CA: Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-1383.
163. Antcliff RJ, Spalton DJ, Stanford MR, et al: Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-772.
164. Degenring RF, Jonas JB: Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 2003;87:361.
165. Sonoda KH, Enaida H, Ueno A, et al: Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol 2003;87:1010-1014.
166. Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R Jr: Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-574.
167. Angunawela RI, Heatley CJ, Williamson TH, et al: Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: long-term management and outcome. Acta Ophthalmol Scand 2005;83:595-599.
168. Larsson J, Hvarfner C, Skarin A: Intravitreal triamcinolone in two patients with refractory macular oedema in sarcoid uveitis. Acta Ophthalmol Scand 2005;83:618-619.
169. Marullo M, Perilli R, Balestrazzi E: Intravitreal triamcinolone in cystoid macular edema due to uveitis and repeated surgery after a penetrating trauma. Eur J Ophthalmol 2004;14:581-583.
170. Benhamou N, Massin P, Haouchine B, et al: Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-249.
171. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA: Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
172. Karaçorlu M, Özdemir H, Karaçorlu S: Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003;81:648-652.
173. Boscia F, Furino C, Dammacco R, et al: Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol 2005;15:89-95.
174. Chen SD, Lochhead J, McDonald B, Patel CK: Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol 2004;88:843-844.
175. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384-386. (Pubitemid 36904101)
176. Jonas JB: Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol 2004;137:367-368.
177. Jonas JB, Spandau UH: Repeated intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia. Acta Ophthalmol Scand 2006;84:436.
178. Özdemir H, Karaçorlu M, Karaçorlu S: Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol 2005;243:734-736.
179. Sutter FK, Gillies MC: Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 2003;121:1491-1493.
180. Shields CL, Demirci H, Dai V, et al: Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 2005;25:868-874.
181. Jonas JB: Intravitreal triamcinolone for treatment of chronic focal immunological corneal graft reaction. Graefes Arch Clin Exp Ophthalmol 2003;241:779-780.
182. Alldredge CD, Garretson BR: Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-116.
183. Martínez JA: Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 2003;121:1658-1659.
184. Smithen LM, Spaide RF: Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884-885.
185. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 2003;13:575-576. (Pubitemid 38208842)
186. Klais CM, Spaide RF: Intravitreal triamcinolone acetonide injection in ocular ischemic syndrome. Retina 2004;24:459-461.
187. Jonas JB: Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment. Br J Ophthalmol 2004;88:587-588.
188. Özdemir H, Karaçorlu M, Karaçorlu S: Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 2005;83:248-251. (Pubitemid 40561839)
189. Intravitreal Triamcinolone Ophthalmologica 2011;225:1-20 17
190. Sallum JM, Farah ME, Saraiva VS: Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide: case report. Adv Exp Med Biol 2003;533:79-81.
191. Saraiva VS, Sallum JM, Farah ME: Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2003;34:398-400.
192. Rakic JM, Zelinkova M, Comhaire-Poutchinian Y, Galand A, Duchateau E: Treatment of Graves macular edema with intravitreal injection of corticosteroids (in French). Bull Soc Belge Ophtalmol 2003;288:43-48.
193. Hogan A, Behan U, Kilmartin DJ: Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 2005;89:1109-1111.
194. Inoue M, Nagai N, Shinoda H, et al: Intravitreal injection of triamcinolone acetonide for cystoid macular edema resistant to vitreous surgery (in Japanese). Nippon Ganka Gakkai Zasshi 2004;108:92-97.
195. Navajas EV, Costa RA, Farah ME, Cardillo JA, Bonomo PP: Indocyanine-green-mediated photothrombosis combined with intravitreal triamcinolone for the treatment of choroidal neovascularization in serpiginous choroiditis. Eye (Lond) 2003;17:563-566.
196. Scott IU, Flynn HW Jr, Rosenfeld PJ: Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 2003;136:737-739.
197. Jonas JB, Kamppeter BA: Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol 2005;89:386-387.
198. Gharbiya M, Grandinetti F, Balacco Gabrieli C: Intravitreal triamcinolone for macular detachment following panretinal photocoagulation. Eye (Lond) 2005;19:818-820.
199. Jarin RR, Teoh SC, Lim TH: Resolution of severe macular oedema in adult Coats' syndrome with high-dose intravitreal triamcinolone acetonide. Eye (Lond) 2006;20:163-165.
200. Jonas JB, Kamppeter B: Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea 2006;25:240-241. (Pubitemid 43362732)
201. Karaçorlu M, Mudun B, Özdemir H, Karaçorlu SA, Bürümcek E: Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol 2004;138:289-291.
202. Kramer M, Ehrlich R, Snir M, et al: Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behçet's disease. Am J Ophthalmol 2004;138:666-667.
203. Kyto JP, Angerman S, Lumiste E, Paloheimo M, Summanen PA: Intravitreal triamcinolone acetonide as an adjuvant therapy to panretinal photocoagulation for proliferative retinopathy with high-risk characteristics in type 1 diabetes: case report with 22 weeks follow-up. Acta Ophthalmol Scand 2005;83:605-608.
204. Lahey JM, Kearney JJ, Cheung MC: Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone. Br J Ophthalmol 2004;88:1100-1101.
205. Özdemir H, Karaçorlu M, Karaçorlu S: Resolution of foveal pseudocyst after intravitreal triamcinolone acetonide. Acta Ophthalmol Scand 2005;83:619-620. (Pubitemid 41488641)
206. Pathengay A, Pilli S, Das T: Intravitreal triamcinolone acetonide in Eales' disease: a case report. Eye (Lond) 2005;19:711-713.
207. Peiretti E, Klancnik JM Jr, Spaide RF, Yannuzzi L: Choroidal neovascularization in Sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina 2005;25:377-379.
208. Wilson CA, Berkowitz BA, Sato Y, et al: Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-1159.
209. Spaide RF, Fisher Y: Removal of adherent cortical vitreous plaques without removing the internal limiting membrane in the repair of macular detachments in highly myopic eyes. Retina 2005;25:290-295.
210. Peyman GA, Cheema R, Conway MD, Fang T: Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554-555.
211. Sakamoto T, Miyazaki M, Hisatomi T, et al: Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
212. Burk SE, da Mata AP, Snyder ME, et al: Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 2003;29:645-651.
213. Matsumoto H, Enaida H, Hisatomi T, et al: Retinal detachment in morning glory syndrome treated by triamcinolone-acetonideassisted pars plana vitrectomy. Retina 2003;23:569-572.
214. Enaida H, Sakamoto T, Ueno A, et al: Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol 2003;135:243-246. (Pubitemid 36151813)
215. Takeuchi M, Katagiri Y, Usui M: Residual triamcinolone acetonide in the macular hole after vitrectomy. Am J Ophthalmol 2003;136:1174-1176.
216. Kimura H, Kuroda S, Nagata M: Triamcinoloneacetonide-assisted peeling of the internal limiting membrane. Am J Ophthalmol 2004;137:172-173.
217. Yamakiri K, Uchino E, Kimura K, Sakamoto T: Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol 2004;138:650-652.
218. Yamamoto N, Ozaki N, Murakami K: Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica 2004;218:248-256.
219. Yamamoto N, Ozaki N, Murakami K: Double visualization using triamcinolone acetonide and trypan blue during stage 3 macular hole surgery. Ophthalmologica 2004;218:297-305.
220. Satofuka S, Inoue M, Shinoda K, et al: Adherence of intravitreally injected triamcinolone acetonide to the denuded retinal surface after internal limiting membrane peeling. Retina 2005;25:672-673.
221. Chen TY, Yang CM, Liu KR: Intravitreal triamcinolone staining observation of residual undetached cortical vitreous after posterior vitreous detachment. Eye (Lond) 2006;20:423-427.
222. Karaçorlu M, Özdemir H, Arf Karaçorlu S: Does intravitreal-triamcinolone-acetonideassisted peeling of the internal limiting membrane effect the outcome of macular hole surgery? Graefes Arch Clin Exp Ophthalmol 2005;243:754-757.
223. Jonas JB, Kreissig I, Budde WM, Degenring RF: Cataract surgery combined with intravitreal injection of triamcinolone acetonide. Eur J Ophthalmol 2005;15:329-335. (Pubitemid 40943929)
224. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF: Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
225. Beer PM, Bakri SJ, Singh RJ, et al: Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
226. Jonas JB: Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002;86:1450-1451.
227. Jonas JB: Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 2002;86:1066.
228. Gopal L, Sharma T: Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol 2007;55:431-435.
229. Zimmerman TJ, Kooner SK, Sharir M, et al: Textbook of Ocular Pharmacology. Philadelphia, Lippincott-Raven, 1997.
230. Sobrin L, D'Amico DJ: Controversies in intravitreal triamcinolone acetonide use. Int Ophthalmol Clin 2005;45:133-141.
231. Jermak CM, Dellacroce JT, Heffez J, Peyman GA: Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007;52:503-522.
232. Oishi M, Maeda S, Hashida N, et al: Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. Jpn J Ophthalmol 2008;52:489-492.
233. Albini TA, Abd-El-Barr MM, Carvounis PE, et al: Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:390-395.
234. Dierks D, Lei B, Zhang K, Hainsworth DP: Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol 2005;123:1563-1569.
235. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M: Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res 2007;84:342-348.
236. McGee DH, Dembinska O, Gruebbel MM: Evaluation of triamcinolone acetonide following intravitreal injection in New Zealand white rabbits. Int J Toxicol 2005;24:419-425.
237. Kivilçim M, Peyman GA, El-Dessouky ES, et al: Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000;31:474-478.
238. Birinçi H: Surgical results of triamcinoloneassisted pars plana vitrectomy combined with phacoemulsification in diabetic patients. Open Ophthalmol J 2008;2:5-8.
239. Hernández-da Mota SE, Chacón-Lara A, Hernández- Vázquez E: Use of triamcinolone and bevacizumab in 25-gram phacovitrectomy surgery for the treatment of cataract and diabetic macular edema (in Spanish). Arch Soc Esp Oftalmol 2008;83:293-300.
240. Jaissle GB, Bartz-Schmidt KU, Szurman P: Optic atrophy subsequent to epiretinal triamcinolone deposits in an eye following inner limiting membrane peeling (in German). Ophthalmologe 2008;105:575-577.
241. Hauser D, Bukelman A, Pokroy R, et al: Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008;28:825-830.
242. Audren F, Lecleire-Collet A, Erginay A, et al: Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg versus 2 mg. Am J Ophthalmol 2006;142:794-799.
243. Lam DS, Chan CK, Mohamed S, et al: A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203.
244. Shimura M, Nakazawa T, Yasuda K, et al: Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
245. Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C: Threeyear follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
246. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449, 1449.e1-1449.e10.
247. Sivaprasad S, Ockrim Z, Massaoutis P, et al: Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina 2008;28:1435-1442.
248. Lam DS, Chan CK, Mohamed S, et al: Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: sixmonth outcomes. Ophthalmology 2007;114:2162-2167.
249. Kim YM, Chung EJ, Byeon SH, et al: Pars plana vitrectomy with internal limiting membrane peeling compared with intravitreal triamcinolone injection in the treatment of diabetic macular edema. Ophthalmologica 2009;223:17-23.
250. Faghihi H, Roohipoor R, Mohammadi SF, et al: Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-948.
251. Joussen AM, Weiss C, Bauer D, Hilgers RD: Triamcinolone versus inner-limiting membrane peeling in persistent diabetic macular edema (TIME study): design issues and implications. Graefes Arch Clin Exp Ophthalmol 2007;245:1781-1787.
252. Jonas JB, Kreissig I, Degenring RF: Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004;242:184-185. (Pubitemid 38324974)
253. Bardak Y, Çekiç O, Tig SU: Comparison of ICG-assisted ILM peeling and triamcinoloneassisted posterior vitreous removal in diffuse diabetic macular oedema. Eye (Lond) 2006;20:1357-1359.
254. Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H: Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671-1676.
255. Parodi MB, Iacono P, Ravalico G: Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 2008;92:1046-1050.
256. Chung EJ, Lee H, Koh HJ: Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:967-974.
257. Scott IU, Ip MS, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-1128.
258. Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ: Triamcinolone stimulates bFGF production and inhibits TGF-β 1 production by human dermal fibroblasts. Dermatol Surg 2002;28:704-709.
259. Ciulla TA, Criswell MH, Danis RP, et al: Choroidal neovascular membrane inhibition in a laser-treated rat model with intraocular sustained-release triamcinolone acetonide microimplants. Br J Ophthalmol 2003;87:1032-1037.
260. Ciulla TA, Criswell MH, Danis RP, Hill TE: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a lasertreated rat model. Arch Ophthalmol 2001;119:399-404.
261. Danis RP, Bingaman DP, Yang Y, Ladd B: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
262. Folkman J, Ingber DE: Angiostatic steroids: method of discovery and mechanism of action. Ann Surg 1987;206:374-383.
263. Gao H, Qiao X, Gao R, et al: Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res 2004;44:349-356.
264. Penfold PL, Wen L, Madigan MC, et al: Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-465.
265. Intravitreal Triamcinolone Ophthalmologica 2011;225:1-20 19
266. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM: Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-3130.
267. Penfold PL, Wong JG, Gyory J, Billson FA: Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192.
268. Penn JS, Rajaratnam VS, Collier RJ, Clark AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283-290.
269. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P: Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42-48.
270. Wu WC, Cheng KC, Wu HJ: Intravitreal triamcinolone acetonide versus bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (Lond) 2009;23:2215-2222.
271. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB: Intravitreal bevacizumab versus triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2009, E-pub ahead of print.
272. Ip MS, Scott IU, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
273. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-471. (Pubitemid 32273433)
274. Das-Bhaumik RG, Jones NP: Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye 2006;20:934-937.
275. Chan WM, Lim E, Liu DT, Law RW, Lam DS: Intravitreal triamcinolone acetonide for choroidal granuloma in sarcoidosis. Am J Ophthalmol 2005;139:1116-1118.
276. Androudi S, Letko E, Meniconi M, et al: Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005;13:205-212.
277. Pathengay A: Intravitreal triamcinolone acetonide in serpiginous choroidopathy. Indian J Ophthalmol 2005;53:77-79. (Pubitemid 40524401)
278. Shah A, Branley M: Use of intravitreal triamcinolone in the management of birdshot retinochoroidopathy associated with cystoid macular oedema: a case study over a three-year period. Clin Experiment Ophthalmol 2005;33:442-444.
279. Kaynak S, Çelik L, Koçak N, et al: Staining of vitreous with triamcinolone acetonide in retained lens surgery with phacofragmentation. J Cataract Refract Surg 2006;32:56-59.
280. Reinhard T, Sundmacher R: Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: a pilot study. Transpl Int 2002;15:81-88.
281. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW: Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-273.
282. Jonas JB, Bleyl U: Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide. Br J Ophthalmol 2004;88:839-840.
283. Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1664. (Pubitemid 37392386)
284. Jonas JB, Kreissig I, Spandau UH, Harder B: Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-580. (Pubitemid 43265975)
285. Kreissig I, Degenring RF, Jonas JB: Intravitreal triamcinolone acetonide complication of infectious and sterile endophthalmitis (in German). Ophthalmologe 2006;103:30-34. (Pubitemid 43170304)
286. Moshfeghi DM, Kaiser PK, Scott IU, et al: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
287. Nelson ML, Tennant MT, Sivalingam A, et al: Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
288. Parke DW: Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918-919.
289. Westfall AC, Osborn A, Kuhl D, et al: Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-1077.
290. Bucher RS, Hall E, Reed DM, et al: Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch Ophthalmol 2005;123:649-653.
291. Bucher RS, Johnson MW: Microbiologic studies of multiple-dose containers of triamcinolone acetonide and lidocaine hydrochloride. Retina 2005;25:269-271.
292. Amato JE, Lee DH, Santos BA, Akduman L: Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflamm 2005;13:245-247.
293. Garay-Aramburu G, Bilbao-Urtiaga A, Cuesta-García M, Larrauri-Arana A: A case of triamcinolone-induced pseudo-endophthalmitis after vitrectomy (in Spanish). Arch Soc Esp Oftalmol 2005;80:615-617.
294. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA: Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138:489-492.
295. Sutter FK, Gillies MC: Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-974.
296. Agrawal S, Agrawal J, Agrawal TP: Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:679-680.
297. Bakri SJ, Beer PM: The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390.
298. Bui Quoc E, Bodaghi B, Adam R, et al: Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis (in French). J Fr Ophtalmol 2002;25:1048-1056.
299. Chan CK, Fan DS, Chan WM, et al: Ocularhypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study. Eye (Lond) 2005;19:625-630.
300. Detry-Morel M, Escarmelle A, Hermans I: Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bull Soc Belge Ophtalmol 2004:45-51.
301. Gillies MC, Kuzniarz M, Craig J, et al: Intravitrealtriamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-143.
302. Gillies MC, Simpson JM, Billson FA, et al: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
303. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598. (Pubitemid 41108858)
304. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27. (Pubitemid 36071773)
305. Jonas JB, Kreissig I, Degenring R: Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003;121:729-730. (Pubitemid 36554480)
306. Özkiris A, Erkiliç K: Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
307. Park HY, Yi K, Kim HK: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-127.
308. Singh IP, Ahmad SI, Yeh D, et al: Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138:286-287.
309. Smithen LM, Ober MD, Maranan L, Spaide RF: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
310. Becker B, Bresnick G, Chevrette L, et al: Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol 1966;76:477-483.
311. Jonas JB, Degenring R, Kreissig I, Akkoyun I: Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-1055. (Pubitemid 40040030)
312. Jaissle GB, Szurman P, Bartz-Schmidt KU: Ocular side effects and complications of intravitreal triamcinolone acetonide injection (in German). Ophthalmologe 2004;101:121-128.
313. Macky TA, Oelkers C, Rix U, et al: Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002;45:1122-1127.
314. Çekiç O, Chang S, Tseng JJ, et al: Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139:993-998.
315. Jonas JB, Degenring R, Vossmerbauemer U, Kamppeter B: Frequency of cataract surgery after intravitreal injection of highdosage triamcinolone acetonide. Eur J Ophthalmol 2005;15:462-464. (Pubitemid 41152966)
316. Bouzas EA, Karadimas P, Pournaras CJ: Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-448.
317. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S: Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-249.
318. Kai W, Yanrong J, Xiaoxin L: Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 2006;244:1152-1159.
319. Macky TA, Helmy D, El Shazly N: Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007;245:817-824.
320. Lang Y, Zemel E, Miller B, Perlman I: Retinal toxicity of intravitreal Kenalog in albino rabbits. Retina 2007;27:778-788. (Pubitemid 47051776)
321. Tokuda K, Tsukamoto T, Fujisawa S, Matsubara M: Evaluation of toxicity due to vital stains in isolated rat retinas. Acta Ophthalmol Scand 2004;82:189-194.
322. Degenring RF, Jonas JB: Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:1142-1143.
323. Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS: Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004;48:236-242.
324. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS: The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003;44:5293-5300.
325. Mora P, Eperon S, Felt-Baeyens O, et al: Trans-scleral diffusion of triamcinolone acetonide. Curr Eye Res 2005;30:355-361.
326. Okubo A, Ito M, Kamisasanuki T, Sakamoto T: Visual improvement following trans-Tenon retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2005;243:837-839.
327. Tunc M, Onder HI, Kaya M: Posterior sub-Tenon capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology 2005;112:1086-1091.
328. dal Canto AJ, Downs-Kelly E, Perry JD: Ptosis and orbital fat prolapse after posterior sub-Tenon capsule triamcinolone injection. Ophthalmology 2005;112:1092-1097.
329. Hernáez-Ortega MC, Soto-Pedre E: A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 2004;35:350-351.
330. Oishi M, Maeda S, Nakamura A, et al: Examination of purification methods and development of intravitreal injection of triamcinolone acetonide. Jpn J Ophthalmol 2005;49:384-387.
331. Aiello LP, Brucker AJ, Chang S, et al: Evolving guidelines for intravitreous injections. Retina 2004;24: S3-S19.
332. Blumenkranz MS, Claflin A, Hajek AS: Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 1984;102:598-604.